Biocompatible and Antifouling Linear Poly(<i>N</i>‑(2-hydroxypropyl)methacrylamide)-Coated Capillaries via Aqueous RAFT Polymerization Method for Clinical Proteomics Analysis of No... by Mengqing Yang (13253917)

Subjects:

Biocompatible and Antifouling Linear Poly(<i>N</i>‑(2-hydroxypropyl)methacrylamide)-Coated Capillaries via Aqueous RAFT Polymerization Method for Clinical Proteomics Analysis of No... by Mengqing Yang (13253917)

Subjects:

Biocompatible and Antifouling Linear Poly(<i>N</i>‑(2-hydroxypropyl)methacrylamide)-Coated Capillaries via Aqueous RAFT Polymerization Method for Clinical Proteomics Analysis of No... by Mengqing Yang (13253917)

Subjects:

Biocompatible and Antifouling Linear Poly(<i>N</i>‑(2-hydroxypropyl)methacrylamide)-Coated Capillaries via Aqueous RAFT Polymerization Method for Clinical Proteomics Analysis of No... by Mengqing Yang (13253917)

Subjects:

This is the raw data of IHC-2 、qPCR、Masson and HE in Rat、qPCR in human peritoneal solution and qPCR in Met-5A cell. by Yangyang Yin (14323701)

Subjects:

Image 5_Using sodium glycodeoxycholate to develop a temporary infant-like gut barrier model, in vitro.pdf by Francesca Bietto (21511316)

“…</p>Results<p>Our research demonstrates that GDC decreases Caco-2/HT29-MTX Trans-Epithelial Electrical Resistance (TEER) and increases paracellular permeability, without inflammation or cytotoxicity. …”

Demographics and baseline characteristics of the safety population. by Rahsan Erdem (11726357)

Subjects:

iOWH032 inhibits cholera toxin-induced secretion in a mouse closed-loop model. by Rahsan Erdem (11726357)

Subjects:

Grading of stool consistency and diarrhea severity. by Rahsan Erdem (11726357)

Subjects:

Secondary efficacy endpoints for the modified intent-to-treat population. by Rahsan Erdem (11726357)

Subjects:

Study drug–related treatment-emergent adverse events by system organ class and preferred term in the safety population. by Rahsan Erdem (11726357)

Subjects:

Source data for Fig 1. by Rahsan Erdem (11726357)

Subjects:

Diarrheal stool output rate overall and by blood type status in the modified intent-to-treat population. by Rahsan Erdem (11726357)

Subjects:

Source data for S1 and S2 Figs. by Rahsan Erdem (11726357)

Subjects:

Source data for Fig 2. by Rahsan Erdem (11726357)

Subjects:

Consolidated Standards for Reporting of Trials flow diagram. by Rahsan Erdem (11726357)

Subjects:

iOWH032 inhibits cholera toxin-induced fecal output in a cecectomized rat model. by Rahsan Erdem (11726357)

Subjects:

Source data for Fig 3. by Rahsan Erdem (11726357)

Subjects:

Scatterplot of iOWH032 plasma concentrations versus diarrheal stool output rate. by Rahsan Erdem (11726357)

Subjects:

Reverse cumulative distribution plot for diarrheal stool output rate overall in the modified intent-to-treat population. by Rahsan Erdem (11726357)

Subjects: